%0 Journal Article %A E. Andrew Balas %A Charmi Patel %A Ben Ewing %A Nauka Patel %A Tiana Curry %A Scott Wise %A Yara H Abdelgawad %T Analysis of recurrent research pathways for assessing and improving effectiveness in life sciences laboratories %D 2023 %R 10.1101/2023.01.09.23284360 %J medRxiv %P 2023.01.09.23284360 %X Background Life sciences research often turns out to be ineffective. Our aim was to develop a method for mapping repetitive research processes, detecting practice variations, and exploring inefficiencies.Methods Three samples of R&I projects were used: companion diagnostics of cancer treatments, identification of COVID-19 variants, and COVID-19 vaccine development. Major steps involved: defined starting points, desired end points; measurement of transition times and success rates; exploration of variations, and recommendations for improved efficiency.Results Over 50% of CDX developments failed to reach market simultaneously with new drugs. There were significant variations among phases of co-development (Bartlett test P<0.001). Length of time in vaccine development also shows variations (P<0.0001). Similarly, subject participation indicates unexplained variations in trials (Phase I: 489.7 (±461.8); Phase II: 857.3 (±450.1); Phase III: 35402 (±18079).Conclusion Analysis of repetitive research processes can highlight inefficiencies and show ways to improve quality and productivity in life sciences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYes. The authors recognize partial funding support from the US National Institutes of Health (R01 GM146338-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAugusta University CommonsR&IResearch and InnovationCOVID-19coronavirus disease of 2019SARS-COV-2Severe acute respiratory syndrome coronavirus 2PubMedPublisher MEDLINEUSPTOUnited States Patent and Trademark OfficeR&DResearch and DevelopmentACEAngiotensin Converting EnzymeCDXCompanion Diagnostics %U https://www.medrxiv.org/content/medrxiv/early/2023/01/10/2023.01.09.23284360.full.pdf